Cargando…

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.

Non-alcoholic fatty liver disease and steatohepatitis are highly associated with obesity and type 2 diabetes mellitus. Cotadutide, a GLP-1R/GcgR agonist, was shown to reduce blood glycemia, body weight and hepatic steatosis in patients with T2DM. Here, we demonstrate that the effects of Cotadutide t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boland, Michelle L., Laker, Rhianna C., Mather, Karly, Nawrocki, Arkadiusz, Oldham, Stephanie, Boland, Brandon B., Lewis, Hilary, Conway, James, Naylor, Jacqueline, Guionaud, Silvia, Feigh, Michael, Veidal, Sanne S., Lantier, Louise, McGuinness, Owen P., Grimsby, Joseph, Rondinone, Cristina M., Jermutus, Lutz, Larsen, Martin R., Trevaskis, James L., Rhodes, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258337/ https://www.ncbi.nlm.nih.gov/pubmed/32478287 http://dx.doi.org/10.1038/s42255-020-0209-6

Ejemplares similares

Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction
por: Boland, Michelle L, et al.
Publicado: (2018)

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
por: Jouihan, Hani, et al.
Publicado: (2017)

Structural analysis of the dual agonism at GLP-1R and GCGR
por: Li, Yang, et al.
Publicado: (2023)

Peptide-YY(3-36)/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries
por: Boland, Brandon B., et al.
Publicado: (2021)

Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery
por: Mizera, Mikołaj, et al.
Publicado: (2021)

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
por: Nahra, Rajaa, et al.
Publicado: (2021)

Robust anti‐obesity and metabolic effects of a dual GLP‐1/glucagon receptor peptide agonist in rodents and non‐human primates
por: Henderson, S. J., et al.
Publicado: (2016)

EGCG, GCG, TFDG, or TSA Inhibiting Melanin Synthesis by Downregulating MC1R Expression
por: Wang, Wei, et al.
Publicado: (2023)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
por: Song, Nazi, et al.
Publicado: (2022)

Construction and analysis of the ceRNA network hsa_circ_0031968/miR-3611/GCG in lung adenocarcinoma
por: Yang, Yang, et al.
Publicado: (2021)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
por: Pickford, Phil, et al.
Publicado: (2021)

A GCG expansion (GCG)(11) in polyadenylate-binding protein nuclear 1 gene caused oculopharyngeal muscular dystrophy in a Chinese family
por: Ye, Juan, et al.
Publicado: (2011)

Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR
por: Wang, Huixia, et al.
Publicado: (2023)

A directed evolution design of a GCG-specific DNA hemimethylase
por: Gerasimaitė, Rūta, et al.
Publicado: (2009)

Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice
por: Boland, Brandon B., et al.
Publicado: (2019)

Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis
por: Ali, Mahmoud M., et al.
Publicado: (2022)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
por: Zimmermann, Tina, et al.
Publicado: (2022)

Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
por: Parker, Victoria E. R., et al.
Publicado: (2022)

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
por: Boland, Michelle L, et al.
Publicado: (2019)

A tetrahelical DNA fold adopted by tandem repeats of alternating GGG and GCG tracts
por: Kocman, Vojč, et al.
Publicado: (2014)

AAV GCG-EGFP, a new tool to identify glucagon-secreting α-cells
por: Tudurí, Eva, et al.
Publicado: (2019)

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose
por: Zhang, Yulin, et al.
Publicado: (2021)

The dynamic plasticity of insulin production in β-cells
por: Boland, Brandon B., et al.
Publicado: (2017)

Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose
por: Geething, Nathan C., et al.
Publicado: (2010)

Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion
por: Panaro, Brandon L., et al.
Publicado: (2020)

High glucose-induced glucagon resistance and membrane distribution of GCGR revealed by super-resolution imaging
por: Gao, Jing, et al.
Publicado: (2023)

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein
por: Zhao, Ming, et al.
Publicado: (2021)

A Cre-driver rat model for anatomical and functional analysis of glucagon (Gcg)-expressing cells in the brain and periphery()
por: Zheng, Huiyuan, et al.
Publicado: (2022)

The PYY/Y2R-Deficient Mouse Responds Normally to High-Fat Diet and Gastric Bypass Surgery
por: Boland, Brandon, et al.
Publicado: (2019)

The first pediatric case of glucagon receptor defect due to biallelic mutations in GCGR is identified by newborn screening of elevated arginine
por: Li, Hong, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study
por: Klein, Gernot, et al.
Publicado: (2023)

DNA Methylation in Skeletal Muscle Stem Cell Specification, Proliferation, and Differentiation
por: Laker, Rhianna C., et al.
Publicado: (2016)

Establishment of a long-term stable β-cell line and its application to analyze the effect of Gcg expression on insulin secretion
por: Miyazaki, Satsuki, et al.
Publicado: (2021)

Glucagon Promotes Gluconeogenesis through the GCGR/PKA/CREB/PGC-1α Pathway in Hepatocytes of the Japanese Flounder Paralichthys olivaceus
por: Yang, Mengxi, et al.
Publicado: (2023)

MiR‐22 modulates the expression of lipogenesis‐related genes and promotes hepatic steatosis in vitro
por: Yang, Zhuo, et al.
Publicado: (2020)

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes
por: Yang, Jianxin, et al.
Publicado: (2011)

Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cells
por: Godfrey, Jason, et al.
Publicado: (2022)

Survival in endometrial cancer in relation to minimally invasive surgery or open surgery – a Swedish Gynecologic Cancer Group (SweGCG) study
por: Borgfeldt, Christer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m6s1unn7ki889566d1ufa3sap8